RecruitingPhase 4Drug trialDupilumab De-escalation in Pediatric Atopic DermatitisThis is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.